Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third leading cause of cancer-related death, accounting for as many as 500,000 deaths annually. Most patients with HCC also suffer from coexisting cirrhosis, which is the major clinical risk factor for HCC and is correlated to hepatitis B virus or hepatitis C virus (HCV) infection and more rarely to alcoholism, hemochromatosis and primary biliary cirrhosis.
Surgery, percutaneous ablation, TACE (transarterial chemoembolization) and liver transplantation are effective treatments for early stage HCC, but they fail to achieve disease control in about 60% of cases. In patients ineligible for local treatment, conventional chemotherapy, either with a single agent or with a combination of drugs, is not recommended. In fact, although response rates of 10% to 20% have been reported, the survival benefit of chemotherapy has never been confirmed (1).
Two large, independent phase III trials indicated a small, but statistically significant survival advantage of2-3 months in patients with advanced HCC treated with sorafenib, in respect to placebo (2) (3) . On the basis of this evidence, NCCN Clinical Practice Guidelines in Oncologyrv currently recommend first-line treatment with sorafenib in patients ineligible for liver transplantation.
Wepresent the case ofan HCC patient who showed clinical, biochemical and radiological response after 4 cycles of sorafenib, but had to discontinue therapy because of a myocardial infarction. Despite the patient having received no anti-tumor treatment since sorafenib interruption about a year ago, he has not shown any signs of disease progression and is currently closely followed-up. Speculation about this unusual, durable response to sorafenib is presented together with a concise survey of the literature on this topic.
Case Report
The patient, a 60-year-old man, was on follow-up at the Department of Endocrinology and Molecular and Clinical Oncology of University Federico II of Naples because of a previous gastric B cell non-Hodgkin lymphoma from which he had fully recovered after surgery and chemotherapy treatment.
He presented a history of cigarette use (20 pack-ayear) and hepatitis C-related cirrhosis.
In April 2008, he referred a 10 kg weight loss during the previous 2 months and complained about severe asthenia. His ECOG status was I. On physical examination, the liver appeared enlarged and painful on palpation, with an irregular surface and increased consistency. An abdominal CT scan with contrast found a dominant mass in the right lobe of the liver, with other smaller nodules, all of which showed an increased uptake on FOG PET-TC (maximum SUV, 12.9) (Fig. IA) . Serum alpha-fetoprotein levels were 609,90 U/ml (upper limit value, 15 U/ml). Therefore, the patient had a stage B HCC, according to Barcelona clinic liver cancer (BCLC) staging classification.
In May 2008, a biopsy confirmed the diagnosis of HCC and a TACE was performed. A month after the procedure, the patient, who presented a wellpreserved liver and heart function (Child-Pugh A class, ejection fraction of 65%), was started on sorafenib (400 mg twice a day, every day for a 6week cycle). The administered dose was halved to 200 mg twice a day shortly after the start of treatment, owing to the onset of febrile neutropenia. Main toxicity to treatment was hand-foot syndrome, which caused frequent therapy discontinuation.
In October 2008, after four cycles of sorafenib, the patient's clinical status appeared dramatically improved. He had regained weight and the liver was reduced in size and not painful on palpation. His ECOG performance status was O. A CT scan showed shrinkage of the main lesion, with a 50% reduction in its largest diameters and disappearance of most of the satellite nodes. PET-TAC showed abnormal accumulation in the liver (maximum SUV, 3.8), reduced in respect to previous PET-TC ( Fig. I B) , and there was also a steep reduction in serum alphafetoprotein levels (5 U/ml) (Fig. 2) .
In November 2008, the patient suffered a myocardial infarction, documented by ECG and abnormal serum troponin I levels. Heart ultrasound revealed akinesia of the mid and basal segment of inferoposterior wall, and an ejection fraction of 35% precluded continuation with sorafenib treatment. A close monitoring of the patient's heart and liver function was initiated, with monthly blood analysis of alpha-fetoprotein and liver and heart enzymes and trimestralliver and heart ultrasound.
At follow-up, the patient did not show any biochemical sign of cardiac necrosis, with a partially restored heart function (40% ejection fraction at six months and 45% ejection fraction at 12 months). Surprisingly, despite the absence of any anti-tumor treatment for about I year and stable liver disease ( Fig. I C, SUV 3.4) , no clinical, biochemical or radiological evidence of tumor progression has been detected. At the present time (January 20 I0), the patient is alive, progression-free and presents an ECOG performance status of I.
DISCUSSION
Two large, multicenter, randomized, controlled trials, conducted in North America and Europe (the SHARP trial) (2) and in the Asia-Pacific region (3) recently showed that sorafenib provided a statistically significant survival advantage in patients with advanced HCC and a well-preserved liver function, in respect to placebo (10.7 vs 7.9 months (2) and 6.5 vs 4.2 months (3), respectively, in the treatment and in the placebo group). These two trials also reported an advantage in time to radiological progression (5.5 vs 2.8 months (2) and 2.8 vs 1.4 months (3), respectively, in the treatment and in the placebo group), but both ofthem reported a very low response rate of 2-5%, suggesting that such a surrogate endpoint is probably inadequate to evaluate treatment efficacy. The treatment appeared well tolerated, with gastrointestinal toxicity and hand-foot syndrome ofall grades reported as the most frequent treatment-related adverse effects. It was of great importance to conduct two separate trials in different geographical areas, because while HCV is the leading cause of HCC in Europe and North America, HBV is the leading cause of HCC in the Asia-pacific area, which validated the results of the SHARP trial in the setting of a mainly HBV-related disease.
The long progression-free survival of 12 months and survival of 19 months obtained in our patient are impressive and far in excess of those reported (2) (3) . We can speculate that sorafenib treatment determines a durable inhibition of angiogenesis in a particular, rare subset of patients, which could be identified if other cases like ours were reported. A dilemma regards the possible continuation oftherapy with sorafenib in the case of progressive disease on follow-up. Multiple tyrosine-kinase inhibitors cause heart toxicity (4-5), but in consideration of the improvement of ejection fraction at follow-up, therapy effectiveness and lack of alternative effective treatments for HCC, it is our intention to continue sorafenib administration, in cases of progressive disease.
In conclusion, the case here described is the first reported case of long-lasting response to sorafenib in a patient with HCC. At the present time, our understanding is limited, but a peculiar subset of HCC patients might be identified, should other cases like ours be presented.
